Galena Biopharma Income from Cont. Ops Quarterly
Galena Biopharma Income from Cont. Ops Quarterly Chart
Galena Biopharma Historical Income from Cont. Ops Quarterly DataPro Data Export
There is no data for the selected date range.
|Data for this Date Range|
|Dec. 31, 2012||Go Pro|
|Sept. 30, 2012||Go Pro|
|June 30, 2012||Go Pro|
|March 31, 2012||Go Pro|
|Dec. 31, 2011||Go Pro|
|Sept. 30, 2011||Go Pro|
|June 30, 2011||Go Pro|
|March 31, 2011||Go Pro|
|Dec. 31, 2010||Go Pro|
|Sept. 30, 2010||Go Pro|
|June 30, 2010||Go Pro|
|March 31, 2010||Go Pro|
|Dec. 31, 2009||Go Pro|
About Income from Continuing Operations
Income Statement line item that does not account extraordinary items and discontinued operations. This metric is frequently used because it excludes items that are unlikely to happen the next reporting period.
For instance, if MSFT had five billion in Income, and 2 billion in an exceptional item charge, its income would be a reported 3 billion. Because the exceptional charge is unlikely to be repeated in the next quarter, some investors prefer to see what MSFT's income was BEFORE charges.
View Income from Cont. Ops Quarterly for GALE.
Start Your YCharts Pro Gold Membership.
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
YCharts Pro is only $49/month, and comes with a 14-day free trial.Get Started Now
Already a YCharts Pro Gold Member? Sign in here.
GALE Income from Cont. Ops Quarterly Benchmarks
|Celldex Therapeutics||Go Pro|
|ImmunoCellular Therapeutics||Go Pro|
|Northwest Biotherapeutics||Go Pro|
GALE Income from Cont. Ops Quarterly Rankings
8524 of 16773
755 of 1408 in Healthcare
206 of 453 in Biotechnology
GALE Income from Cont. Ops Quarterly Range, Past 5 Years
|Minimum||Go Pro||Mar 2012|
|Maximum||Go Pro||Dec 2011|
Street Insider Jun 17
Fool Jun 14
Fool Jun 5
Street Insider Jun 3
Street Insider May 31